The University of Kansas Cancer Center (KUCC) administration office is the principal organizational component through which the Associate Directors, Research Program Leaders and Shared Resource Directors execute their responsibilities to Cancer Center members. The administrative office provides administrative and fiscal oversight of Cancer Center functions. These functions include grant development; human resources; communications; Cancer Center Support Grant management; Cancer Center, Clinical Trial Office and shared resource financial administration; outreach and information dissemination; and information technology.
The aims of the administrative office are to: 1. Provide direction, leadership and cost effective management to allow efficient use of resources for KUCC members across campuses and throughout its consortium partners; 2. Establish and maintain consistent information organization and dissemination among research programs and shared resources to ensure aims are met; 3. Enhance research and education opportunities for KUCC members, students and post-doctoral fellows by providing strategies that encourage and facilitate collaborative, cross-disciplinary investigations across campuses and consortium partners; and 4. Impact cancer in KUCC's catchment area by leveraging consortium partners, key stakeholders, community advocates and regional leaders to develop and promote research collaboration and implementation of evidence-based cancer prevention, diagnosis, treatment and survivorship practices through community partnerships directed toward urban underserved and rural communities. The KUCC Senior Leadership team is made up of the Director, Deputy Director, Associate Directors and the Chief Operating Officer. This group meets every other week to evaluate cross-programmatic and multi-campus activities including pilot project programs, research symposia, seminars and conferences; review the progress of the research programs and shared resources; and discuss and make decisions related to the budget, resource allocation, membership, space, leadership appointments and strategic initiatives. This group aims to advance the cancer focus of KUCC by fostering collaborative initiatives, defining areas of strength, addressing areas of weakness and integrating basic scientists and clinicians for both the advancement of basic discoveries and training and educational efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA168524-07
Application #
9528478
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
7
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Kansas
Department
Type
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Snyder, Vusala; Reed-Newman, Tamika C; Arnold, Levi et al. (2018) Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front Oncol 8:203
Chen, Yvonnes; Fowler, Carina H; Papa, Vlad B et al. (2018) Adolescents' behavioral and neural responses to e-cigarette advertising. Addict Biol 23:761-771
Mudaranthakam, Dinesh Pal; Thompson, Jeffrey; Hu, Jinxiang et al. (2018) A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials. JAMIA Open 1:166-171
Ranjan, Atul; Iyer, Swathi V; Ward, Christopher et al. (2018) MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget 9:21429-21443
Brody, Jonathan R; Dixon, Dan A (2018) Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 9:e1469
Sharma, P; Barlow, W E; Godwin, A K et al. (2018) Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol 29:654-660
Campos, Camila D M; Gamage, Sachindra S T; Jackson, Joshua M et al. (2018) Microfluidic-based solid phase extraction of cell free DNA. Lab Chip 18:3459-3470
Kfoury, Najla; Sun, Tao; Yu, Kwanha et al. (2018) Cooperative p16 and p21 action protects female astrocytes from transformation. Acta Neuropathol Commun 6:12
Young, Eric D; Strom, Kyle; Tsue, Ashley F et al. (2018) Automated quantitative image analysis for ex vivo metastasis assays reveals differing lung composition requirements for metastasis suppression by KISS1. Clin Exp Metastasis 35:77-86

Showing the most recent 10 out of 177 publications